Literature DB >> 6356456

Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.

M J Elms, I H Bunce, P G Bundesen, D B Rylatt, A J Webber, P P Masci, A N Whitaker.   

Abstract

We have prepared a monoclonal antibody which recognises an antigenic determinant on D dimer, a specific fragment resulting from the degradation of crosslinked fibrin. This antibody has been used in the development of an enzyme-linked immunoassay for D dimer and related degradation products containing crosslinked gamma-gamma chains, to provide a simple assay of circulating crosslinked fibrin degradation products suitable for clinical use. Since these crosslinked fibrin degradation products are characteristic of fibrinolysis, as distinct from fibrinogenolysis, their measurement should aid in the diagnosis, evaluation and monitoring of thrombotic and thrombolytic states. In preliminary studies, low concentrations of crosslinked fibrin derivatives were detected in normal sera. High levels were found in 30/30 patients with disseminated intravascular coagulation and in the majority of patients having deep venous thrombosis or pulmonary embolism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356456

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Usefulness of a latex agglutination assay for FDP D-dimer to demonstrate the presence of postmortem blood.

Authors:  Koichi Sakurada; Ikuko Sakai; Kazumasa Sekiguchi; Tomoko Shiraishi; Hiroshi Ikegaya; Ken-ichi Yoshida
Journal:  Int J Legal Med       Date:  2005-01-15       Impact factor: 2.686

Review 2.  Antibody imaging in the evaluation of cardiovascular diseases.

Authors:  B A Khaw; J Narula
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

Review 3.  New strategies in the determination of fibrin and fibrin(ogen) derivatives by monoclonal antibodies.

Authors:  W Nieuwenhuizen
Journal:  Blut       Date:  1988-11

4.  Cytokine and coagulation characteristics of retrieved blood after arthroplasty.

Authors:  M Kristiansson; M Soop; L Saraste; K G Sundqvist; A M Suontaka; M Blomback
Journal:  Intensive Care Med       Date:  1995-12       Impact factor: 17.440

5.  A prospective, randomized, blinded, and placebo-controlled trial of intraoperative intra-arterial urokinase infusion during lower extremity revascularization. Regional and systemic effects.

Authors:  A J Comerota; A K Rao; R C Throm; C I Skibinski; G J Beck; S Ghosh; L Sun; G R Curl; J J Ricotta; R A Graor
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

6.  Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study.

Authors:  R Bellomo; H Teede; N Boyce
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

7.  Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies.

Authors:  A N Whitaker; M J Elms; P P Masci; P G Bundesen; D B Rylatt; A J Webber; I H Bunce
Journal:  J Clin Pathol       Date:  1984-08       Impact factor: 3.411

8.  Fibrinolytic response to tumor necrosis factor in healthy subjects.

Authors:  T van der Poll; M Levi; H R Büller; S J van Deventer; J P de Boer; C E Hack; J W ten Cate
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

Review 9.  Measuring fibrinolysis: from research to routine diagnostic assays.

Authors:  C Longstaff
Journal:  J Thromb Haemost       Date:  2018-02-17       Impact factor: 5.824

10.  Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer. Japan Advanced Breast Cancer Study Group and Japan Clinical Oncology Group.

Authors: 
Journal:  Jpn J Cancer Res       Date:  1993-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.